<p>A, dose-response curves were obtained on day 4 from cells treated with a series of six 1:1 dilutions of PXD101. B, Dm of PXD101 on day 4 was calculated using CompuSyn software for each cell line. Among seven follicular cell-derived thyroid cancer lines, ATC cell lines (8305C, 8505C, KAT18 and KAT4C) had the lowest Dm, followed by well-differentiated follicular (WRO82-1) and papillary (BHP7-13) cancer, and follicular undifferentiated thyroid cancer (FRO81-2). Medullary thyroid cancer cells (TT) also had low Dm. C, PXD101 induced acetylation of histone H3 and histone H4 in a dose-dependent manner. PXD101 also increased acetylation of tubulin in BHP7-13, WRO82-1 and 8505C.</p
